Blood- and urinary levels of different carnitine-esters during administration of oxaliplatin based chemotherapy

Blood- and urinary levels of different carnitine-esters during administration of oxaliplatin based chemotherapy - Carnitine levels during oxaliplatin infusion

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46342

Enrollment

Registered

2018-09-06

Start date

2019-03-12

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carnitine metabolisme en excretie, deficiëntie, interactie met chemotherapie (oxaliplatin) Defeciency/lack of/reduction of concentration of carnitine (an amino acid or half-vitamin) during/caused by treatment with chemotherapy (oxaliplatin)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Age >18 years 3. Start treatment with oxaliplatin-based chemotherapy 4. Understanding the Dutch language

Exclusion criteria

Exclusion criteria: 1. Patients with known primary carnitine deficiency (congenital) 2. Patients on haemodialysis or peritoneal dialysis 3. Patients with epilepsy 4. Current treatment with valproic acid or zidovudine 5. Current use of carnitine supplements or use of carnitine supplements in the past 3 months 6. Pre-existent neuropathy or comorbid disorder causing neuropathy 7. Previous treatment with neurotoxic chemotherapy 8. Participation in an intervention study on CIPN (e.g. Frozen Gloves)

Design outcomes

Primary

Measure	Time frame
The entire carnitine spectrum in plasma will be measured using a precursor ion scan. Urinary analysis will be done to measure the concentration of L-carnitine in urine.	—

Countries

Netherlands

Outcome results